Identification of the Determinants of Plexiform Neurofibroma Morbidity in Pediatric and Young Adult Neurofibromatosis Type 1 Patients: A Pilot Multivariate Approach
Open Access
Abstract
Background: Plexiform neurofibromas (PNs) are histologically benign peripheral nerve sheath tumors associated with neurofibromatosis type 1 (NF1) and often lead to significant morbidity due to growth. Management includes watchful waiting, surgery for partial debulking, and, since recently, systemic treatment with MEK inhibitors. However, due to the scarcity of natural history studies, our understanding of the natural progression of PNs to guide clinicians in deciding in whom and when to intervene is scarce. This study aims to describe the characteristics of NF1 patients with PNs and compare those at high risk for PN progression or experiencing significant morbidity from PN (complex PN) with NF1 patients with PNs of lower complexity. Methods: In this retrospective cohort study using clinical data from hospital records of NF1 patients with PNs seen at the Sophia Children’s Hospital in the Netherlands between 2012 and 2023, we assessed determinants of clinical phenotypes and PN characteristics predictive of outcomes, including PN complexity and the timing of intervention for PN. We assessed the outcomes using logistic regression analysis and Cox regression. Results: Ninety patients with a median age at last evaluation of 15.7 years and a median follow-up duration of 9.8 years were included. Out of 90 individuals with a benign PN, 37 developed plexiform neurofibroma morbidity during follow-up. Older age was (corrected for pathogenic NF1 variant and PN location) significantly associated with plexiform neurofibroma morbidity. Cox regression revealed that craniofacial and trunk PNs were associated with a higher intervention hazard compared to limb PNs. Conclusion: Our pilot multivariate approach identified older age and the location of the PN to be mostly associated with a higher chance of plexiform neurofibroma morbidity and higher intervention hazard. This may contribute to decisions regarding in whom and when to initiate treatment in NF1 patients with PNs.Keywords
This publication has 35 references indexed in Scilit:
- ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1eClinicalMedicine, 2023
- Clinical Characteristics and Management of Children and Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas in Denmark: A Nationwide StudyOncology and Therapy, 2022
- Pediatric malignancies in neurofibromatosis type 1: A population‐based cohort studyInternational Journal of Cancer, 2019
- Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk SyndromesFamilial Cancer, 2018
- Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1Academic Radiology, 2017
- Development of emotional and behavioral problems in neurofibromatosis type 1 during young childhoodAmerican Journal of Medical Genetics Part A, 2017
- Internal tumor burden in neurofibromatosis Type I patients with large NF1 deletionsGenes, Chromosomes and Cancer, 2012
- Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Frequency and Associated Clinical DeficitsThe Journal of Pediatrics, 2011
- Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven TumorsCancer Cell, 2011
- Birth incidence and prevalence of tumor‐prone syndromes: Estimates from a UK family genetic register serviceAmerican Journal of Medical Genetics Part A, 2010